Comparative Pharmacology
Head-to-head clinical analysis: BETAPACE AF versus TIMOLOL MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAPACE AF versus TIMOLOL MALEATE.
BETAPACE AF vs TIMOLOL MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sotalol is a class III antiarrhythmic agent that also has non-cardioselective beta-adrenergic receptor blocking activity. It prolongs the cardiac action potential duration by blocking potassium channels (IKr), thereby prolonging the QT interval and refractory periods.
Non-selective beta-adrenergic receptor antagonist (beta-blocker). Competitively blocks beta1 and beta2 receptors, reducing heart rate, myocardial contractility, and cardiac output. Also decreases aqueous humor production in the eye by blocking beta2 receptors on ciliary epithelium.
80 mg orally twice daily. For atrial fibrillation/flutter, initiate at 80 mg twice daily; may increase after 2-3 days to 120 mg twice daily if needed. Maximum 120 mg twice daily.
Systemic: 1 drop of 0.25% or 0.5% solution in affected eye(s) twice daily. Additional indication: 0.5% gel-forming solution once daily. Oral: 10 mg twice daily, may increase to 20 mg twice daily if needed.
None Documented
None Documented
Terminal elimination half-life: 12 hours (range 10–20 hours) in patients with normal renal function; prolonged in renal impairment (up to 42 hours in severe impairment).
2-3 hours (terminal); prolonged in hepatic impairment
Primarily renal (unchanged drug and metabolites); approximately 40% excreted as unchanged sotalol in urine, with additional metabolites via fecal route (~10%). Biliary excretion minimal (<5%).
Renal: 20% unchanged; biliary/fecal: 80% as metabolites
Category C
Category A/B
Beta-Blocker
Beta-Blocker